David Parry-Jones

Title: David Parry-Jones: Innovator in Isoindolinone Derivatives

Introduction

David Parry-Jones is a notable inventor based in Welwyn Garden, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of isoindolinone derivatives. With a total of two patents to his name, his work has the potential to impact cancer treatment and related therapies.

Latest Patents

David's latest patents focus on isoindolinone inhibitors of the MDM2-P53 interaction. The inventions relate to processes for preparing isoindolin-1-one derivatives, specifically the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. Additionally, the patents cover crystalline forms of this compound and its salts, showcasing the innovative approaches taken by Parry-Jones in his research.

Career Highlights

Throughout his career, David has worked with prominent organizations such as Astex Therapeutics Limited and Cancer Research Technology Limited. His experience in these companies has allowed him to develop and refine his expertise in drug development and innovation.

Collaborations

David has collaborated with notable colleagues, including Steven Howard and Jeffrey David St Denis. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

David Parry-Jones is a distinguished inventor whose work in isoindolinone derivatives holds promise for future advancements in cancer treatment. His contributions to the field are noteworthy and reflect his dedication to innovation in pharmaceuticals.